(J Am Heart Assoc. 2018;7:e007686 DOI: [10.1161/JAHA.117.007686](10.1161/JAHA.117.007686).)29386205

 {#jah32785-sec-0004}

Clinical PerspectiveWhat Is New?LXR (liver X receptor) regulates local DNA methylation profiles in atherosclerosis by binding to a DR2‐containing DNA motif embedded in *Alu* short interspersed nuclear elements.LXR regulates the expression of 3 differential methylation motif−containing long noncoding RNAs that are differentially expressed in atherosclerotic and normal human aortas.What Are the Clinical Implications?The findings may help define useful targets for molecular therapies for cardiovascular disease.

 {#jah32785-sec-0008}

A detailed understanding of the DNA methylome of the atherosclerotic lesion is expected to yield novel insights into molecular mechanisms of cardiovascular disease (CVD) and to improve diagnostic and therapeutic strategies.[1](#jah32785-bib-0001){ref-type="ref"}, [2](#jah32785-bib-0002){ref-type="ref"} Recent microarray‐based and genome sequencing--based work using blood vessel type--matched and donor‐matched samples indicates that the DNA methylome of the atherosclerotic plaque undergoes dynamic changes during disease progression. These include hypermethylation during the stable phase followed by progressive demethylation in the symptomatic postrupture phase.[3](#jah32785-bib-0003){ref-type="ref"}, [4](#jah32785-bib-0004){ref-type="ref"}, [5](#jah32785-bib-0005){ref-type="ref"} The dynamic nature of the atherosclerotic lesion methylome is likely to account for some of the published conflicting reports, particularly the ones pointing to a genome‐wide hypomethylation resembling the cancer methylome.[6](#jah32785-bib-0006){ref-type="ref"}, [7](#jah32785-bib-0007){ref-type="ref"}, [8](#jah32785-bib-0008){ref-type="ref"}, [9](#jah32785-bib-0009){ref-type="ref"} In apparent support for the pathological relevance of the initial DNA hypermethylation wave in atherosclerosis, work in mouse models showed that the biochemical inhibition of DNA methyltransferase (DNMT) activity greatly reduces lesion size and inflammatory markers.[10](#jah32785-bib-0010){ref-type="ref"}, [11](#jah32785-bib-0011){ref-type="ref"}, [12](#jah32785-bib-0012){ref-type="ref"} Conversely, overexpression of the DNMT family member DNMT1 exacerbates atherosclerosis.[13](#jah32785-bib-0013){ref-type="ref"}

A related urgent task is to identify the molecular pathways leading to atherosclerosis‐specific DNA methylation signatures in the vascular tissue. Homocysteine has received significant attention because of its participation in the biochemical machinery that generates the universal methyl donor S‐adenosylmethionine and its role as an independent CVD risk factor; however, the evidence is conflicting.[14](#jah32785-bib-0014){ref-type="ref"} Homocysteine induces vascular endothelial cell growth arrest and apoptosis by promoter hypermethylation‐mediated silencing of critical loci, a response that is reversed by biochemical DNMT inhibition.[15](#jah32785-bib-0015){ref-type="ref"} Furthermore, homocysteine stimulates cell proliferation through microRNA‐mediated upregulation of the DNMT member DNMT3 in cultured vascular smooth muscle.[16](#jah32785-bib-0016){ref-type="ref"}, [17](#jah32785-bib-0017){ref-type="ref"} Another explored topic has been the signaling pathways triggered by lipoprotein components, such as triglyceride‐rich lipoproteins and the fatty acid arachidonate. Both induce global hypermethylation in THP‐1 cells, and arachidonate‐induced DNA methylation profiles overlap with atherosclerosis‐specific signatures.[18](#jah32785-bib-0018){ref-type="ref"}, [19](#jah32785-bib-0019){ref-type="ref"} Hypermethylation is observed both within genic and repetitive *Alu* elements. Importantly, a causal effect of lipids on DNA methylation profiles in vivo has been demonstrated recently.[20](#jah32785-bib-0020){ref-type="ref"}

In the present work, we sought to gain further insights into pathways leading to atherosclerosis‐specific DNA methylation signatures. To this end, we functionally characterized a 29‐bp DNA motif that we previously identified by a CpG island (CGI) array‐based survey of human coronary atherosclerotic plaques obtained from ischemic cardiopathy patients undergoing revascularization surgery.[8](#jah32785-bib-0008){ref-type="ref"} That motif is present in sequences flanking ≈55% of CGIs that undergo demethylation in those samples and thus was named *differential methylation motif* (DMM). In this study, we used a combination of molecular and epigenomics approaches to test the hypothesis that a DMM is associated with atherosclerosis‐specific DNA methylation and expression profiles. We discuss our findings in the context of the current knowledge of the epigenomics of atherosclerosis.

Methods {#jah32785-sec-0009}
=======

Yeast one‐Hybrid Assay {#jah32785-sec-0010}
----------------------

The DMM (5′‐ATCACTTGAGGTCAGGAGTTCGAGACCAG‐3′) was cloned into the pHISi vector (Clontech) upstream to imidazoleglycerol‐phosphate dehydratase (*HIS3*) between the *EcoRI* and *XbaI* restriction sites. The construct contained 2 DMM copies in tandem to achieve a robust *HIS3* activation. The DMM‐*HIS3* cassette‐containing fragment generated by *ApaI* digestion was inserted into the genome of the *Saccharomyces cerevisiae* YM4271 strain (genotype: MATa, ura3‐52, his3‐200, ade2‐101, lys2‐801, leu2‐3, 112, trp1‐901, tyr1‐501, gal4‐D512, gal80‐D538, ade5::hisG) to generate the bait strain. The latter was transformed using 0.5 mg of a Gal4 activation domain (AD)--human aorta cDNA fusion library (prey) in the Matchmaker pACT2 vector (Clontech). *HIS3* expression allows cells to grow on medium lacking histidine. Transformed cells were selected in medium lacking leucine, uracil, and histidine, supplemented with the highly stringent 75 mmol/L 3‐aminotriazole, an inhibitor of the *HIS3* gene product. These conditions select for strong HIS3 expressants versus revertants. Library clones extracted from growing colonies were sequenced and identified with the GenBank database ( National Center for Biotechnology Information). A subset of those clones was tested for activation specificity by further rounds of transformation into the bait strain and selection in 75 mmol/L 3‐aminotriazole--supplemented medium. To test for sequence binding specificity, mutant bait strains in which the AGGTCA portion of the DMM (positions 9--14) was either scrambled (GATAGC) or deleted were transformed and selected with increasing 3‐aminotriazole doses (0--50 mmol/L).

Human Vascular Samples {#jah32785-sec-0011}
----------------------

Authorization by institutional ethical committees and sample description were reported previously.[3](#jah32785-bib-0003){ref-type="ref"}

Cell Culture {#jah32785-sec-0012}
------------

Monocyte THP‐1 cells were cultured in RPMI‐1640 containing [l]{.smallcaps}‐glutamate (Life Technologies), 10% (vol/vol) FBS (Life Technologies), 5% CO~2~, 37°C. For differentiation to macrophages, ≈10^7^ cells were treated with 50 ng/mL PMA (phorbol 12‐myristate 13‐acetate; Sigma‐Aldrich) for 4 hours, followed by 25 ng/mL PMA for 4 days with a medium change on the second day. Lipid‐loaded THP‐1 macrophages (LLMas) were obtained by culture in medium supplemented with 10% heat‐inactivated, hypertrigliceridemic (\>200 mg/dL triglyceride) human serum instead of FBS. Those serum samples were in excess of the amount used for routine blood lipid profile tests in the department\'s clinical laboratory and normally would have been disposed of; lipid loading was assessed by oil red O staining of fixed cells. Stimulation with DMSO‐dissolved GW3965 or T0901317 (1 μmol/L in either case) or DMSO alone (control) was carried out for 24 hours. Final DMSO concentration in the medium was 0.01%. HEK293 cells were cultured in DMEM supplemented with [l]{.smallcaps}‐glutamate (Life Technologies), 10% (vol/vol) FBS, 5% CO~2~, 37°C, at cell density \<10^6^ cells/mL.

Chromatin Immunoprecipitation {#jah32785-sec-0013}
-----------------------------

THP‐1 monocytes were stimulated with 1 μmol/L GW3965 dissolved in DMSO or with DMSO alone (controls) at the same final DMSO concentration (0.01%) for 24 hours. As reported, 20 million cells were processed for each treatment.[21](#jah32785-bib-0021){ref-type="ref"} Briefly, sonication settings were 20 seconds at amplitude 90, 15 times. The anti‐LXRB (anti--liver X receptor β) antibody was chromatin immunoprecipitation (ChIP) grade (cb56237; Abcam). Washes and DNA recovery were performed, as described.[22](#jah32785-bib-0022){ref-type="ref"} Precipitated DNA was amplified with gene‐specific oligonucleotides indicated in Table [S1](#jah32785-sup-0001){ref-type="supplementary-material"}. An aliquot (5%) of the preimmunoprecipitation extract was amplified in parallel (input control). Polymerase chain reaction (PCR) products were run in 1× Tris/Borate/EDTA buffer (TBE), 2% agarose gels. All experiments were carried out at least in biological and technical triplicate.

*Alu* Combined Bisulfite Restriction Analysis {#jah32785-sec-0014}
---------------------------------------------

DNA extracted from THP‐1 cells was modified with sodium bisulfite with the EZ DNA Methylation‐Gold kit (Zymo Research), as recommended by the manufacturer and, PCR‐amplified with the primers indicated in Table [S1](#jah32785-sup-0001){ref-type="supplementary-material"}. The primers amplify most *Alu* subfamilies, except *FLA, FLAM_A, FLAM_C, Jr, Jr4, Jo, Sq2, Sq10, Sc5, Yf2*, and *Yh9*. The product was digested with *Taq*I, and fragments were quantified by densitometry, as described.[23](#jah32785-bib-0023){ref-type="ref"}

Gene‐Specific Methylation Profiling {#jah32785-sec-0015}
-----------------------------------

THP‐1 monocytes and macrophage genomic DNA was treated with sodium bisulfite using the EZ DNA Methylation‐Gold system (Zymo). PCR products obtained with the gene‐specific primers listed in Table [S1](#jah32785-sup-0001){ref-type="supplementary-material"} were cloned, sequenced, and analyzed with the Kismeth software.[24](#jah32785-bib-0024){ref-type="ref"}

Bioinformatics {#jah32785-sec-0016}
--------------

For whole‐genome bisulfite sequencing data extraction, raw data from a previously published study[3](#jah32785-bib-0003){ref-type="ref"} of 1 atherosclerotic (grade VII)/normal human aortic tissue pair was downloaded from GEO data set [GSE46327](GSE46327). A random set of 50 million reads from each sample was aligned to the *AluS* reference using BSMAP version 2.90,[25](#jah32785-bib-0025){ref-type="ref"} with default parameters and allowing up to 2 mismatches. Methylation was called from the aligned reads with the methratio.py script provided with BSMAP, without removing duplicates.

The coordinates of *Alu* elements were obtained from the UCSC Genome Browser, and the sequence of *Alu* elements was used as published in Repbase ([girinst.org/repbase](http://girinst.org/repbase)).[26](#jah32785-bib-0026){ref-type="ref"} Long noncoding RNA (lncRNA) coordinates were obtained from RNA sequencing libraries available in MiTranscriptome (58 648 lncRNAs; [mitranscriptome.org](http://mitranscriptome.org)).[27](#jah32785-bib-0027){ref-type="ref"} The reference GRCh37/hg19 human genome was used in all cases. The atherosclerotic lesions used in the present study were previously obtained and analyzed by the Infinium Human Methylation 450 BeadChip (450K array).[3](#jah32785-bib-0003){ref-type="ref"} The methylation level for each cytosine was expressed as a β value between 0 (unmethylated) and 1 (methylated). *Alu* flanking sequence methylation was extracted from 450K array data for ±100‐bp or ±2‐kb flanking sequences and averaged every 10 or 50 bp, respectively.

Phylogenesis {#jah32785-sec-0017}
------------

The analysis was performed with the Neighbor‐Joining method in MEGA 7, using 37 *Alu* subfamilies. The evolutionary distances were computed using the maximum composite likelihood method and are expressed as the number of base substitutions per site.

Gene Expression {#jah32785-sec-0018}
---------------

THP‐1 cells and aorta RNA were extracted with the Trizol method (Life Technologies) and treated with TURBO DNase (Life Technologies). The cDNA was synthesized using 500 ng (THP‐1 cells) or 400 ng (aorta) RNA, with a poly‐dT oligonucleotide, and the reverse transcriptase SuperScript ll (Life Technologies). Platinum (Life Technologies) was used for PCR. For *Alu* semiquantitative expression, the primers indicated in Table [S1](#jah32785-sup-0001){ref-type="supplementary-material"} were used. The primers amplify most subfamilies except *FLA, FLAM_A, FLAM_C, FAM, FRAM, Jr, Jr4, Jb, Jo, Sp, Yc5, Yg6, Yh9, Ye5, Yf5*, and *Yk12*. For all other transcripts, real‐time PCR assay was performed using SYBR GreenER qPCR SuperMix (Life Technologies) in a StepOne System using the primers indicated in Table [S1](#jah32785-sup-0001){ref-type="supplementary-material"}. Relative expression units were calculated against *GAPDH*.

lncRNA‐Operated Transcriptional Regulation *In Cis* {#jah32785-sec-0019}
---------------------------------------------------

*lncACACA* and *lncSREBF1* cDNAs were amplified with high‐fidelity Platinum Taq DNA polymerase (Invitrogen) and inserted into pTracer‐SV40 (Thermo Fisher Scientific) using the *Apa*I and *Spe*I restriction sites. The *ACACA* and *SREBF1* promoters were amplified from human genomic DNA with Platinum Taq DNA polymerase (primer sequence available on request) and inserted upstream to the firefly luciferase CDS in pGL4 (Promega) using the *Hind*III and *Xho*I restriction sites. HEK293 cells were first transfected with the lncRNA cDNA (2.5 μg plasmid) using Lipofectamine 3000 (Invitrogen) in 6‐well plates, as recommended by the manufacturer. At 24 hours later, cells were transfected with the promoter‐firefly luciferase construct (0.1 μg) in 96‐well plates. The *Renilla* luciferase vector (pRL‐TK; Promega) was cotransfected and used as expression control. Normalized expression was calculated as a firefly/*Renilla* luciferase activity ratio. Luciferase assays were performed in 96‐well chemoluminescence plates using the Dual‐Glo system (Promega), according to the manufacturer\'s instructions. Each assay was performed in triplicate.

Statistical Analyses {#jah32785-sec-0020}
--------------------

ANOVA with the Scheffé post hoc test was used for expression and methylation data. The χ^2^ test was used for atherosclerotic/normal donor‐matched aortic sample pairs. Tests were performed using SPSS software for Windows (version 19.0; IBM Corp) and R (version 3.2.0; R Foundation for Statistical Computing).

Results {#jah32785-sec-0021}
=======

Genomic and Sequence Features of the DMM {#jah32785-sec-0022}
----------------------------------------

The DMM sequence yielded by the DNA motif search program MEME is partially degenerated.[8](#jah32785-bib-0008){ref-type="ref"} However, the reference DMM sequence---consisting of the most represented bases in each position---will hereafter be referred to as DMM if not specified otherwise. A BLAST‐based homology search revealed that DMM is homologous to *Alu*, an abundant primate‐specific retrotransposon family present in ≈1.1 million copies in the human genome.[28](#jah32785-bib-0028){ref-type="ref"}, [29](#jah32785-bib-0029){ref-type="ref"} Homology is particularly high with the *AluS* subfamily, with *AluSz* bearing an intact DMM. *AluS* and *AluJ* members show \>93% homology with reference DMM and account for ≈750 000 *Alu* copies. Conversely, homology was comparatively low with *AluY* (69--75%; Figure [1](#jah32785-fig-0001){ref-type="fig"}A and [1](#jah32785-fig-0001){ref-type="fig"}B; Figure [S1](#jah32785-sup-0001){ref-type="supplementary-material"}). In addition, a search for conserved features of DMM revealed the presence of a DR2 nuclear receptor (NR) response element (Figure [1](#jah32785-fig-0001){ref-type="fig"}B). DR2 consists of 2 direct RGKTCA repeats (R and K indicate A or G and G or T, respectively) separated by a 2‐nucleotide spacer. The presence of DR2 in *Alu* has been documented.[30](#jah32785-bib-0030){ref-type="ref"}, [31](#jah32785-bib-0031){ref-type="ref"} Notably, the *Alu* DR2 is functionally important because it binds the NR retinoic acid receptor to produce RNA polymerase III transcripts during stem cell differentiation.[32](#jah32785-bib-0032){ref-type="ref"} Furthermore, the entire *Alu* B box, a conserved RNA polymerase III--binding site that regulates *Alu* transcription, is embedded within DMM (Figure [1](#jah32785-fig-0001){ref-type="fig"}B).[33](#jah32785-bib-0033){ref-type="ref"}

![DMM is part of *Alu*. A, Homology‐based clustering analysis of DMM and *Alu* subfamilies. B, Sequence alignment of DMM and the closest *Alu* subfamilies and position of DMM within *Alu*. The consensus *AluY* sequence is shown. The position (bp) of DMM relative to the *AluS* 5′ end is indicated above the alignment. Mismatches to DMM are on a white background. The DR2 repeat is in upper case. The boxed sequence in DMM is the *Alu* B box. The asterisks indicate the position of the 2 CpGs profiled by the combined bisulfite restriction analysis. DMM indicates differential methylation motif.](JAH3-7-e007686-g001){#jah32785-fig-0001}

LXRB Binds to the DMM {#jah32785-sec-0023}
---------------------

The aforementioned conserved sequence features hinted that DMM is a putative docking site for DR2‐binding epigenetic modifiers.[34](#jah32785-bib-0034){ref-type="ref"}, [35](#jah32785-bib-0035){ref-type="ref"} We therefore sought DMM‐binding proteins by screening a Gal4 AD‐human aorta cDNA fusion library (prey) by the yeast 1‐hybrid assay. As bait, we used a DMM‐*HIS3* reporter construct integrated into the *S. cerevisiae* genome (bait strain). The initial screen yielded a total of 45 independent colonies able to grow on histidine‐depleted medium, and from 38 of those, Gal4 AD‐cDNA clones were successfully sequenced. Ten clones were in‐frame (Table [S2](#jah32785-sup-0001){ref-type="supplementary-material"}); of these, 5 encoded LXRB (or NR1H2). Repeated transformations of the Gal4 AD‐*LXRB* cDNA fusion into the bait strain revealed a specific and robust growth phenotype, pointing to LXRB as a strong DMM‐binding protein candidate. Furthermore, DR2 was necessary for the DMM--LXRB interaction, as either scrambling or deleting the 5′‐most of the 2 DR2 direct repeats (AGGTCA) of DMM abrogated Gal4 AD‐*LXRB* cDNA fusion‐induced growth on selecting medium (Figure [2](#jah32785-fig-0002){ref-type="fig"}A). These results are pathobiologically plausible because LXRs (liver X receptors; LXRA \[LXR α\] and LXRB members), a family of NRs activated by the endogenous ligands oxysterols, play pivotal roles both in cholesterol efflux from the vascular wall and in the control of atherosclerosis progression.[36](#jah32785-bib-0036){ref-type="ref"}, [37](#jah32785-bib-0037){ref-type="ref"}, [38](#jah32785-bib-0038){ref-type="ref"} Furthermore, the described LXR response elements bear sequence similarities to DMM DR2.[39](#jah32785-bib-0039){ref-type="ref"}, [40](#jah32785-bib-0040){ref-type="ref"}

![The LXRB binds to DMM. A, The 1‐hybrid assay showing DR2‐dependent LXRB binding to DMM. Yeast strains with intact or mutated DMM (baits)*‐HIS3* reporter constructs integrated into the genome were created. The strains contained the DMM with an intact (AGGTCA), scrambled (GATAGC), or deleted DR2 5′ repeat (the position of each of the 3 strains on the plates is indicated on the left). Strains were transformed with a Gal4 activation domain--*LXRB* cDNA fusion and cultured in the presence of increasing concentrations of 3‐AT, an inhibitor of the *HIS3* gene product. B, Chromatin immunoprecipitation analysis of DMM--LXRB binding in human THP‐1 cells, in the presence or absence of the LXR agonist GW3965. The position of DMM lncRNAs (gray boxes) and adjacent LXR target genes (black boxes) with genomic coordinates is shown on the left. DMM indicates differential methylation motif; LXRB, liver X receptor β; 3‐AT, 3‐aminotriazole.](JAH3-7-e007686-g002){#jah32785-fig-0002}

One of the other growth‐inducing in‐frame Gal4 AD‐cDNA fusion clones encoded the human Peter Pan homolog (*Drosophila*) (PPAN), a protein involved in ribosome biogenesis, development, and apoptosis regulation.[41](#jah32785-bib-0041){ref-type="ref"}, [42](#jah32785-bib-0042){ref-type="ref"}, [43](#jah32785-bib-0043){ref-type="ref"} Because subsequent experiments revealed a weak phenotype, the DMM--PPAN interaction was not studied further. The remaining 4 in‐frame Gal4 AD‐cDNA fusion clones encoded nonnuclear proteins and thus were discarded.

Next, we sought validation of the DMM--LXRB interaction in human chromatin by ChIP in cultured THP‐1 monocytes. We focused on 3 intergenic DMMs that (1) contain DR2 and are embedded in *Alu* and (2) map in proximity to known LXR target genes. Although the latter genes do not immediately flank the respective lncRNAs, they might be relevant to understanding LXR\'s biological activity (Figure [2](#jah32785-fig-0002){ref-type="fig"}B). The 3 flanking LXR target genes were *ACACA* (acetyl CoA carboxylase), *FASN* (fatty acid synthase), and *SREBF1* (sterol regulatory element binding transcription factor 1).[44](#jah32785-bib-0044){ref-type="ref"}, [45](#jah32785-bib-0045){ref-type="ref"}, [46](#jah32785-bib-0046){ref-type="ref"} In addition, the promoters of the 3 LXR target genes are in CGIs, a feature that may help understanding any effect of DMM on CGI methylation *in cis*.[8](#jah32785-bib-0008){ref-type="ref"} The 3 intergenic DMMs also overlapped with 3 lncRNAs: short interspersed nuclear element/unknown lncRNA (chr17:36,810,109--36,810,324), *RP13‐516M14.4* (chr17:82,290,046--82,292,814), *SMCR2* (chr17:17,674,026--17,677,688; hg38 coordinates in all cases). For simplicity, these will be referred to as *lncACACA*,*lncFASN*, and *lncSREBF1*, respectively (Figure [2](#jah32785-fig-0002){ref-type="fig"}B). The DMM of these lncRNAs is within portions homologous to *AluSx* (*lncACACA lncFASN*) or *AluSq* (*lncSREBF1*). We used the LXR response element in the *SREBF1* promoter and the DMM‐devoid *GAPDH* gene as positive and negative controls, respectively. The ChIP results indicated that LXRB binds to all 3 DMMs (Figure [2](#jah32785-fig-0002){ref-type="fig"}B). To test the reproducibility of our ChIP data, we surveyed a publicly available THP‐1 macrophage LXR ChIP sequencing data set in which exhaustive controls with nonimmune immunoglobulin were performed.[47](#jah32785-bib-0047){ref-type="ref"} Indeed, each of the 3 DMM‐containing lncRNA loci was specifically precipitated by LXR antibodies in the mentioned study (*lncACACA‐*,*lncFASN‐*, and *lncSREBF1‐*specific reads: 612, 2,708 and 1,555, respectively, of 18,304,931 reads). To assess whether LXR activation modifies the DMM--LXRB interaction, we performed ChIP in THP‐1 monocytes stimulated with the LXR synthetic agonist GW3965. No consistent effect of GW3965 was observed (Figure [2](#jah32785-fig-0002){ref-type="fig"}B).

Locus‐Specific and Genome‐Wide Methylation Signatures Associated With *Alu* DMM and Flanking Sequences in Human Vascular Tissue {#jah32785-sec-0024}
-------------------------------------------------------------------------------------------------------------------------------

DMM was initially identified as a motif proximal (≤2 kb) to CGIs that undergo demethylation in advanced plaques.[8](#jah32785-bib-0008){ref-type="ref"} Subsequent more detailed epigenomics showed that CGI demethylation is a widespread phenomenon in the symptomatic atheroma.[5](#jah32785-bib-0005){ref-type="ref"} Therefore, if *Alu*‐embedded DMMs participate in or are the consequence of human atherosclerosis‐specific DNA methylation, the methylation profile within or flanking DMM‐harboring *Alu* should show associations with the genome‐wide atherosclerosis‐specific signature. To probe for locus‐specific methylation profiles, we asked whether CGI CpGs adjacent to the 3 aforementioned lncRNAs show the expected methylation trend, namely, a relative low‐methylation state in postrupture condition compared with stable atherosclerosis. To this end, we profiled 2 kb up and downstream to the 3 lncRNAs using 450K‐based data. The 450K human atheroma methylation data were of stable aortic (n=15 atherosclerotic/normal tissue pairs) and symptomatic or asymptomatic carotid artery (n=19 each) plaque samples.[3](#jah32785-bib-0003){ref-type="ref"}, [4](#jah32785-bib-0004){ref-type="ref"}, [5](#jah32785-bib-0005){ref-type="ref"} This data set is informative for methylation profiles of *Alu*‐flanking sequence but not of *Alu* elements. We identified CpG clusters mapping to a CGI and CGI/shore boundary within 2 kb of *lncACACA* and *lncFASN*, respectively, whereas insufficient data were available for *lncSREBF1*. Both CGIs (neither of which contain any recognizable DMM) showed a significant loss of methylation in the postrupture plaque (*P*=0.030 and *P*=0.034, respectively; paired *t* test; Figure [S2](#jah32785-sup-0001){ref-type="supplementary-material"}).

Next, we asked whether DMM‐harboring *Alu* shows the previously described atherosclerosis‐specific DNA methylation profile. Previous bulk *Alu* whole‐genome bisulfite sequencing data showed ≈15% hypermethylation in stable atherosclerotic aortas compared with donor‐matched normal controls (ie, portions of the same aortas adjacent to the atheroma‐occupied segment; 69.9% and 55.1% methylation, respectively, *P*=4.21×10^−18^, χ^2^ test).[3](#jah32785-bib-0003){ref-type="ref"} After extracting data from the same whole‐genome bisulfite sequencing set, the same trend was observed of the *Alu* subfamily *AluSx* that contains a near‐reference DMM: a significant increase in methylation of atherosclerotic relative to normal aorta by ≈13% (68.3% and 55.0%, respectively; 6384 informative reads on either strand, *P*=2.78×10^−33^; χ^2^ test; Figure [S3](#jah32785-sup-0001){ref-type="supplementary-material"}).

As for *Alu*‐flanking sequences, we gathered 450K methylation data for ±100‐bp and ±2‐kb flanking sequences of *Alu* elements to probe for short‐distance and relatively long‐distance effects. Furthermore, we profiled *Alu*‐flanking non‐CGI and CGI CpGs, based on the rationale that it would enable corroboration of our initial observations that CGIs proximal to DMMs are preferentially demethylated in symptomatic plaques.[5](#jah32785-bib-0005){ref-type="ref"}, [8](#jah32785-bib-0008){ref-type="ref"}

In both atherosclerotic and normal aortas, methylation (β values) abruptly decreases in *Alu*‐flanking sequences both within and outside CGIs (volcano‐shaped profiles in [Figure S4A--S4D](#jah32785-sup-0001){ref-type="supplementary-material"}). In stable atherosclerosis, this is accompanied by a consistent, albeit small, increase in Δβ (≤0.04), relative to their normal counterparts. This was specific of *Alu*‐flanking non‐CGI sequences (compare Figure [S5](#jah32785-sup-0001){ref-type="supplementary-material"}E and [S5](#jah32785-sup-0001){ref-type="supplementary-material"}F with Figure [S5](#jah32785-sup-0001){ref-type="supplementary-material"}G and [S5](#jah32785-sup-0001){ref-type="supplementary-material"}H; compare the upward and downward cone‐shaped profiles of β and Δβ, respectively; Figures [S4](#jah32785-sup-0001){ref-type="supplementary-material"} and [S5](#jah32785-sup-0001){ref-type="supplementary-material"}). Similar trends were observed in symptomatic/asymptomatic carotid plaques (Figure [3](#jah32785-fig-0003){ref-type="fig"}E--[3](#jah32785-fig-0003){ref-type="fig"}H), but the increase in Δβ outside *Alu* was negligible in both CGIs and non‐CGIs (Figure [S5E--S5H](#jah32785-sup-0001){ref-type="supplementary-material"}). Incidentally, CGI methylation was lower than in non‐CGI counterparts in all cases, as expected (Figure [3](#jah32785-fig-0003){ref-type="fig"}; Figure [S4](#jah32785-sup-0001){ref-type="supplementary-material"}).[48](#jah32785-bib-0048){ref-type="ref"} In addition, Δβ was generally more extreme in the normal/stable atheroma aorta sample set compared with the asymptomatic/symptomatic carotid counterpart, particularly in the hypermethylated fraction, as reported (Figure [S5](#jah32785-sup-0001){ref-type="supplementary-material"}).[3](#jah32785-bib-0003){ref-type="ref"}, [5](#jah32785-bib-0005){ref-type="ref"}

![Methylation profile (450K array data) of *Alu*‐flanking non‐CGI and CGI CpGs in human atherosclerosis. ±100‐bp *Alu‐*flanking sequences were surveyed for *Alu* containing a near‐reference (indicated as *Alu*‐DMM) or degenerate DMM in stable atheromas (A through D) or in symptomatic atheromas (E through H) and the respective controls. Each dot indicates the average methylation β of consecutive 10‐bp bins. The number of profiled CpGs is indicated above the respective graph. Solid dots and open triangles indicate atherosclerotic and normal arteries, respectively. CGI indicates CpG island; DMM, differential methylation motif.](JAH3-7-e007686-g003){#jah32785-fig-0003}

Next, we compared methylation profiles of sequences flanking DMM *Alu* and degenerate DMM *Alu*. The latter were defined as displaying mismatches within and outside DMM DR2 and clustering on a separate branch when *Alu* was classified for DR2 homology. The elements in question include *AluJb*,*AluJo*,*FAM*,*FLA*, and *FRAM* (Figure [S6](#jah32785-sup-0001){ref-type="supplementary-material"}, upper part). As further control, we surveyed sequences flanking mammalian‐wide interspersed repeats (*MIR*). *MIR*s are short interspersed nuclear elements that lack any detectable DMM or DR2 and that show an inconsistent methylation profile in atherosclerosis.[3](#jah32785-bib-0003){ref-type="ref"}, [49](#jah32785-bib-0049){ref-type="ref"} If DMM is functionally relevant, atherosclerosis‐specific DNA methylation profiles should be absent or more relaxed proximal to degenerate DMM--harboring *Alu* and *MIR*s. As for any differential association with reference and degenerate DMMs, CGI methylation was significantly lower at short distance from the former (*P*=1.4×10^−6^; compare Figure [3](#jah32785-fig-0003){ref-type="fig"}C and [3](#jah32785-fig-0003){ref-type="fig"}D). A significant difference in Δβ comparing reference DMM with either degenerate DMM or *MIR* was also observed (*P*=10^−5^ and *P*=3.3×10^−4^, respectively; compare Figure [S5](#jah32785-sup-0001){ref-type="supplementary-material"}C with Figures [S5](#jah32785-sup-0001){ref-type="supplementary-material"}D and [S7](#jah32785-sup-0001){ref-type="supplementary-material"}B). In addition, a general increase in Δβ variability was apparent in degenerate DMM--harboring *Alu*‐flanking sequences regardless of *Alu* distance compared with intact DMM--harboring counterparts, more clearly so in 2‐kb flanking sequences (compare Figure [S5](#jah32785-sup-0001){ref-type="supplementary-material"}A and [S5](#jah32785-sup-0001){ref-type="supplementary-material"}B, Figure [S5](#jah32785-sup-0001){ref-type="supplementary-material"}C and [S5](#jah32785-sup-0001){ref-type="supplementary-material"}D, Figure [S5](#jah32785-sup-0001){ref-type="supplementary-material"}E and [S5](#jah32785-sup-0001){ref-type="supplementary-material"}F, and Figure [S5](#jah32785-sup-0001){ref-type="supplementary-material"}G and [S5](#jah32785-sup-0001){ref-type="supplementary-material"}H). In symptomatic plaques, a higher methylation level was also observed close to degenerate DMM in CGIs in this sample set (*P*=0.03; compare Figure [3](#jah32785-fig-0003){ref-type="fig"}G and [3](#jah32785-fig-0003){ref-type="fig"}H). The data suggest that LXR might bind degenerate DMM--harboring *Alu* to a lesser extent compared with intact DMM--harboring counterparts. We verified this hypothesis in human LXR ChIP sequencing data.[47](#jah32785-bib-0047){ref-type="ref"} The number of reads corresponding to intact DMM--*Alu* was ≈3.7‐fold higher than degenerate DMM counterparts (130 and 35, respectively). This ratio is not significantly different from the observed count ratio (Figure [3](#jah32785-fig-0003){ref-type="fig"}; χ^2^ test), suggesting that LXR binding alone does not explain the differential methylation between sequences flanking the 2 *Alu* sets. We speculate that LXR must bind an intact DMM to recruit additional essential partners.

LXR Agonists Induce Hypermethylation of the *Alu* B Box Region {#jah32785-sec-0025}
--------------------------------------------------------------

In an effort to mechanistically interpret the *Alu* hypermethylation observed in the human atherosclerotic aorta, we asked whether LXRB affects internal methylation of the bulk of *Alu*. To this end, we exploited the serendipitous finding that a previously published combined bisulfite restriction analysis--based *Alu* methylation assay profiles 2 *Alu* CpGs present in most *Alu* subfamilies (see [Methods](#jah32785-sec-0004){ref-type="sec"}).[23](#jah32785-bib-0023){ref-type="ref"} The 2 CpGs are located 29 bp from the B box 5′ end and within the B box and DR2 repeat, respectively (marked by asterisks in Figure [1](#jah32785-fig-0001){ref-type="fig"}B). This locus will be referred to as the *Alu* B box region. As a biological model, we used undifferentiated or differentiated (monocyte and macrophage, respectively) THP‐1 cells, a cellular model of inflammation. In addition, we used LLMas, an approximation of atheroma foam cells. Because of the latter feature, LLMa data can be used to estimate the contribution of lesion macrophages to expression or DNA methylation profiles obtained in the heterogeneous atheroma cell population. The 2 synthetic LXR agonists GW3965 and T0901317 induced a significant increase in methylation of *Alu* B box region (*P*\<0.05 in all cases; ANOVA and Bonferroni post hoc test; Figure [4](#jah32785-fig-0004){ref-type="fig"}). The response was particularly prominent in macrophages and LLMas stimulated with GW3965 (15--17% increase). LXR agonist--induced *Alu* B box region methylation increase is relatively small but comparable with the overall *Alu* hypermethylation observed in atherosclerosis. As for *Alu* expression, inconsistent effects were observed in our experimental conditions in THP‐1 cells and in donor‐matched normal/atherosclerotic aortic tissue pairs (data not shown).

![*Alu* B box methylation in LXR agonist‐stimulated THP‐1 cells and in atheromas. COBRA analysis of *Alu* B box methylation in LXR agonist‐stimulated THP‐1 cells. Open, gray, and solid bars indicate control, T0901317‐, and GW3965‐stimulated cells, respectively. Significant differences with respective controls are shown. \**P*\<0.05 (ANOVA). LLMa indicates lipid‐loaded TH‐1 macrophage; Ma, macrophage; Mo, monocyte.](JAH3-7-e007686-g004){#jah32785-fig-0004}

Methylation Profile of DMM‐Harboring lncRNAs {#jah32785-sec-0026}
--------------------------------------------

Next, we detailed the impact of LXR agonists on methylation profiles within and *in cis* to specific DMM/*Alu*‐harboring transcripts. We focused on the aforementioned *lncACACA*,*lncFASN*, and *lncSREBF1* lncRNAs and the respective flanking CGIs. Data were obtained in monocyte and macrophage THP‐1 stimulated with the LXR agonist GW3965 and controls. LncRNA DMMs were highly methylated (ie, ≈50--100%), and LXR agonists did not exert any notable effect (Figure [S8](#jah32785-sup-0001){ref-type="supplementary-material"}). Similarly, LXR agonists failed to induce any consistent pattern on LXR target gene promoter CGI methylation, except relatively small (≈8%) changes in the *ACACA* promoter. Methylation levels were generally low, as expected for CGIs.[48](#jah32785-bib-0048){ref-type="ref"}

Expression of DMM‐Harboring lncRNAs and Flanking Genes in LXR Agonist‐Stimulated Cells and Human Atheromas {#jah32785-sec-0027}
----------------------------------------------------------------------------------------------------------

The largely negative results of methylation profiling described in the previous paragraph do not rule out that LXR agonists exert methylation‐independent effects on lncRNA expression. Expression of all 3 lncRNAs tended to increase in response to LXR agonist stimulation, although the response in LLMas was relatively blunted (Figure [5](#jah32785-fig-0005){ref-type="fig"}A through [5](#jah32785-fig-0005){ref-type="fig"}C). As for the respective lncRNA‐flanking genes, LXR agonists exerted similar effects (ie, an expression increase; Figure [S9](#jah32785-sup-0001){ref-type="supplementary-material"}A through [S9](#jah32785-sup-0001){ref-type="supplementary-material"}C).

![LncRNA expression in LXR (liver X receptor) agonist--stimulated THP‐1 cells and in aortic atheromas. Quantitative reverse transcription polymerase chain reaction analysis. A through C, Expression in THP‐1 cells. D, Expression in human aortas. \**P*\<0.05; \*\**P*\<0.01 (ANOVA in A--C; paired *t* test in D). A indicates atherosclerotic portion of the human aorta; LLMa, lipid‐loaded TH‐1 macrophage; Ma, macrophage; Mo, monocyte; N, normal portion of the human aorta.](JAH3-7-e007686-g005){#jah32785-fig-0005}

To gain pathobiologically relevant insights, we obtained expression data in human atherosclerotic aortas and compared them with expression profiles in THP‐1 LLMas, a proxy of plaque foam cells, relative to monocytes. In human aortic atheromas, *lncACACA* and *lncSREBF1* expression was increased ≈2‐ and ≈4‐fold, respectively, compared with unaffected matched controls, whereas *lncFASN* showed the opposite profile (Figure [5](#jah32785-fig-0005){ref-type="fig"}D). Baseline (unstimulated cell) expression of *lncACACA* and *lncSREBF1* was significantly increased in LLMas in comparison with monocyte counterparts, whereas *lncFASN* followed the opposite trend (*P*\<0.05 in all cases; Figure [5](#jah32785-fig-0005){ref-type="fig"}A through [5](#jah32785-fig-0005){ref-type="fig"}C, the significant difference is not shown in the figure for simplicity). Thus, the expression trend of the 3 lncRNAs in THP‐1 LLMas compared with monocytes recapitulated the corresponding trend in human atherosclerotic aortas compared with normal tissue.

In contrast, expression of lncRNA‐flanking genes was significantly decreased in atherosclerotic aortas compared with controls in all cases (Figure [S9](#jah32785-sup-0001){ref-type="supplementary-material"}D). Comparing the trend in THP‐1 monocytes and LLMas, only *ACACA* displayed a significant baseline expression difference that mirrored the atheroma profile (compare Figure [S9](#jah32785-sup-0001){ref-type="supplementary-material"}A and [S9](#jah32785-sup-0001){ref-type="supplementary-material"}D).

*In cis* Transcriptional Effect of *lncACACA*,*lncFASN*, and *lncSREBF1* {#jah32785-sec-0028}
------------------------------------------------------------------------

Functionally, it is possible that the surveyed lncRNAs belong to the well‐known *in cis* transcription regulating noncoding RNAs.[50](#jah32785-bib-0050){ref-type="ref"} In that case, lncRNA and respective flanking gene expression patterns should be consistently correlated, either positively or negatively. The data revealed a generally concordant effect of LXR agonists on lncRNA and respective flanking gene expression in THP‐1 cells. In contrast, expression profiles of lncRNAs and flanking genes were opposite for *lncACACA* and *lncSREBF1* but concordant for *lncFASN* in human aortas. To interpret this ambiguity, we directly tested the ability of *lncACACA* and *lncSREBF1* overexpression to affect the transcription of *ACACA* and *SREBF1* promoter‐luciferase reporter constructs, respectively. In the case of *lncFASN*, cloning of the experimental and control constructs could not be successfully completed. Assays were conducted in HEK293 cells given higher transfection efficiency in comparison with THP‐1s. Furthermore, HEK293 cells express LXRB (<http://www.proteinatlas.org/ENSG00000131408-NR1H2/cell>). The data failed to show any clear *in cis* effect of *lncACACA* or *lncSREBF1* overexpression (data not shown).

Discussion {#jah32785-sec-0029}
==========

We provide evidence that the DMM DNA motif, previously proposed as a candidate binding site for factors that induce a low methylation state of CGIs in symptomatic atherosclerotic plaques, is embedded in *Alu*. DMM overlaps with the *Alu* RNA polymerase III--binding B box and contains a DR2 direct repeat that is necessary for LXRB binding. The presence of NR‐binding motifs such as DR2 in *Alu* is well documented, and rules for NR‐type binding specificity have been proposed. In contrast with our data, at least 2 independent human studies showed that LXRs bind mainly to DR4---namely, 2 direct RGKTCA repeats separated by a 4‐nucleotide spacer---in peripheral blood monocyte‐derived macrophages and in THP‐1 macrophages, although a weaker LXR--DR2 interaction was detected in the former model.[40](#jah32785-bib-0040){ref-type="ref"}, [47](#jah32785-bib-0047){ref-type="ref"} The same authors and a mouse liver--based study showed that the DR2 specifically recognizes the NR peroxisome proliferator‐activated receptor γ.[51](#jah32785-bib-0051){ref-type="ref"}, [52](#jah32785-bib-0052){ref-type="ref"} It is possible that binding to *Alu* DR2 is a comparatively minor LXRB activity with specialized functions. At any rate, LXR binding to *Alu* has been documented in the *MPO* promoter[40](#jah32785-bib-0040){ref-type="ref"} and in the autoregulation of *LXRA* gene expression.[53](#jah32785-bib-0053){ref-type="ref"} Interestingly, although it is widely accepted that the LXR binds to its response elements as obligate dimer with RXR (retinoid X receptor), LXRB binds to DR2 in the 1‐hybrid assay despite the absence of RXR in yeast.[54](#jah32785-bib-0054){ref-type="ref"}, [55](#jah32785-bib-0055){ref-type="ref"} Further studies are necessary to understand the frequency and significance of RXR‐independent LXRB binding sites in the genome. In addition, *S. cerevisiae* does not synthesize the physiological LXR agonist oxysterol from cholesterol.[56](#jah32785-bib-0056){ref-type="ref"} Yet homologs of mammalian oxysterol‐binding proteins that are involved in sterol transport have been described in yeast.[57](#jah32785-bib-0057){ref-type="ref"} To our knowledge, whether LXR and yeast oxysterol‐binding proteins share any ligand is unknown. Even if *S. cerevisiae* was devoid of any LXR ligands, specific agonist‐independent LXR DNA binding was detected in human cells and might explain our 1‐hybrid data.[47](#jah32785-bib-0047){ref-type="ref"}

By epigenomics analysis, we gathered evidence supporting an association between DMM and CGI low‐methylation state.[5](#jah32785-bib-0005){ref-type="ref"}, [8](#jah32785-bib-0008){ref-type="ref"} CGIs proximal to near‐reference DMM‐harboring *Alu* are significantly less methylated than CGIs proximal to degenerate DMM--harboring *Alu* or to the DMM‐devoid *MIR* short interspersed nuclear element in human atherosclerotic arteries. Accordingly, methylation of CGIs adjacent to DMM‐harboring lncRNA is significantly reduced in symptomatic versus stable plaques.

The presence of DMM in *Alu* prompted us to dissect the methylation profile within *Alu* elements and in flanking sequences in atherosclerosis and THP‐1 cells. In addition, we tested whether LXR agonists establish any of those profiles. By extrapolation, the observation that LXR agonists hypermethylate the *Alu* B box region suggests an NR‐mediated mechanism for *Alu* hypermethylation, a landmark epigenetic signature of atherosclerosis. Even among other short interspersed nuclear elements, *Alu* is the only repeated sequence that is consistently hypermethylated in the stable atheroma.[3](#jah32785-bib-0003){ref-type="ref"} Furthermore, similar data were obtained in peripheral blood of CVD patients.[58](#jah32785-bib-0058){ref-type="ref"} The effects of LXR agonists are not accompanied by any change in expression of the bulk of *Alu*, in line with evidence that DNA methylation does regulate *Alu* transcription.[59](#jah32785-bib-0059){ref-type="ref"} The observation that the activation of the atheroprotective LXR reinforces an alleged genomic landmark of CVD is unexpected.[37](#jah32785-bib-0037){ref-type="ref"} Our results question any proatherogenic, functional role for *Alu* hypermethylation in atherosclerosis. Rather, the data suggest a compensatory mechanism aimed at further limiting retrotransposition above constraints already imposed by physiological *Alu* hypermethylation. This line of thinking is supported by the comparison of methylation within *Alu* and in flanking sequences. *Alu* is slightly hypomethylated relative to immediate flanking DNA in control aortas. The latter difference is reduced in atherosclerosis, as *Alu* gains methylation to reach the level of immediate flanking DNA, where minimal differences between atherosclerotic aortas and controls are observed. Thus, *Alu* hypermethylation in atherosclerosis results from spreading of the local DNA methylation profile of the normal aorta into *Alu*. Moreover, the data show that with the exception of the CGIs mentioned, *Alu* maps to regions with very little or no differential methylation between atherosclerotic and control aortas. At any rate, *Alu* hypermethylation remains a potentially useful candidate CVD marker.

As for specific *Alu*‐ and DMM‐harboring transcripts, we show that LXR binds to 3 lncRNA loci mapping *in cis* to known LXR target genes. In addition, LXR agonists increase the expression of all 3 lncRNAs in THP‐1 cells. The data echo a recent report that LXR agonists activate 1 enhancer RNA in the same cellular model.[60](#jah32785-bib-0060){ref-type="ref"} In all 3 cases, a consistent direction of expression change was observed between donor‐matched normal and atherosclerotic human aortas and between THP‐1 monocytes and LLMas. This suggests that the observed expression profiles are mainly contributed to by the lesion lipid‐loaded macrophages, although the participation of other cell types in the highly heterogeneous atheroma cannot be ruled out. Functionally, direct molecular experiments and correlative expression analysis failed to support a role for the surveyed lncRNAs as *in cis* transcriptional regulators.

A pending issue is whether the other LXR family member, LXRA, participates in the cellular responses described. LXRA is not present in the human aorta cDNA library used in the 1‐hybrid assay, as judged by reverse transcription PCR. In THP‐1 cells, we detected the *LXRA* transcript (not shown), but a recent study failed to detect the protein by immunoblotting in naïve THP‐1 macrophages.[60](#jah32785-bib-0060){ref-type="ref"} Therefore, at least in the latter cell type, the observed responses to LXR agonists are likely to be mediated by LXRB. At any rate, other factors may bind DMM, since significant binding site sharing has been demonstrated for NRs.[52](#jah32785-bib-0052){ref-type="ref"}

From an evolutionary standpoint, the DMM shows a relatively high homology with phylogenetically old *Alu* subfamilies---*FLAM*,*AluJ*,*AluS*---whereas the recently diverged *AluY* cluster away from the DMM.[61](#jah32785-bib-0061){ref-type="ref"} Remarkably, LXR was shown to induce active enhancer histone marks in loci specifically enriched in *AluJ* and *AluS* in THP‐1 cells.[60](#jah32785-bib-0060){ref-type="ref"} These data are in accordance with the evolutionary importance of *Alu* NR‐binding sites in primates. Accordingly, we previously showed that the portion of the DMM that is homologous to mouse sequences overlaps with the DR2, suggesting biological relevance for the LXR--DMM interaction beyond primates, possibly within the *Alu*‐homolog mouse B1 elements.[8](#jah32785-bib-0008){ref-type="ref"}, [62](#jah32785-bib-0062){ref-type="ref"}

In summary, we provide evidence for an association between the DMM and methylation state of selected CGIs. In addition, we show that LXRs modulate *Alu* methylation and the expression of 3 *Alu*‐harboring lncRNAs that are differentially expressed in atherosclerosis. The data do not support *Alu* hypermethylation as a therapeutic target in atherosclerosis.
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**Table S1.** Primer Sequences

**Table S2.** Candidate Differential Methylation Motif Ligand‐Encoding Human Aorta cDNA Clones Yielded by the 1‐Hybrid Assay

**Figure S1.** Homology between differential methylation motif and *AluY* subfamily members.

**Figure S2.** Methylation profile (450K array data) of long noncoding RNA (lncRNA)--flanking CpG island (CGI) CpGs. The ±2‐kb flanking sequences were surveyed. Gray boxes and arrows in the *x*‐axes indicate lncRNA size/position and transcription direction. Black boxes indicate CGIs. Each dot indicates the methylation Δβ of individual CpGs. Black and gray dots, stable atherosclerotic/normal aortic and symptomatic/asymptomatic carotid samples, respectively. Solid and open dots, hypermethylated and hypomethylated fraction, respectively. Genomic coordinates (hg38) are chr17:36 808 109--36 812 324 (*lncACACA*), chr17:82 288 046--82 294 814 (*lncFASN*) and chr17:17 672 026--17 679 688 (*lncSREBF1*). The scale bar applies to all 3 graphs.

**Figure S3.** *AluSx* CpG methylation profile (WGBS data) in stable atheroma.

**Figure S4.** Methylation profile (450K array data) of *Alu*‐flanking non--CpG island (non‐CGI) and CGI CpGs in human atherosclerosis.

**Figure S5.** Methylation profile (450K array data) of *Alu*‐flanking non--CpG island (non‐CGI) and CGI CpGs.

**Figure S6.** DR2 homology‐based clustering analysis of differential methylation motif and *Alu*.

**Figure S7.** Methylation profile (450K array data) of MIR‐flanking non--CpG island (non‐CGI) and CGI CpGs.

**Figure S8.** Methylation status of long noncoding RNA differential methylation motif and flanking gene promoter CpG island in THP‐1 cells.

**Figure S9.** Long noncoding RNA--flanking gene expression in LXR (liver X receptor) agonist--stimulated THP‐1 cells and in atheromas. Quantitative reverse transcription polymerase chain reaction analysis. A through C, Expression in THP‐1 cells. Open, gray, and solid bars indicate unstimulated, T0901317‐, and GW3965‐stimulated cells, respectively. D, Expression in normal/atherosclerotic paired aortic samples (N and A, respectively). In all cases, significant differences with respective controls or normal aortas are shown. \**P*\<0.05; \*\**P*\<0.01 (ANOVA in A--C; paired *t* test in D). A indicates atherosclerotic portion of the human aorta; LLMa, lipid‐loaded TH‐1 macrophage; Ma, macrophage; Mo, monocyte; N, normal portion of the human aorta.
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